A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 31 Dec 2018
At a glance
- Drugs SAR 440340 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 17 Dec 2018 Planned End Date changed from 27 Aug 2020 to 31 Aug 2020.
- 17 Dec 2018 Planned primary completion date changed from 5 Apr 2019 to 30 Mar 2020.
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.